Back to the directory
Shasqi
Targeting Cancer with Click Chemistry
- Founded
- 2015
- Status
- Active
- Stage
- Growth
- Team size
- 28
- Location
- San Francisco, CA, USA; Remote
- Category
- Biotech & Drug Discovery
- Sector
- Drug Discovery and Delivery
About Shasqi
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.
BiotechTherapeutics
Clinical trials
1 registered trial with this company as lead sponsor, 2020.
- Phases
- Phase 1 (1), Phase 2 (1)
- Status
- Terminated (1)
- Conditions
- Cancer
Source: ClinicalTrials.gov.
Federal research funding
10 NIH awards totalling $9,091,553, FY2021 to FY2025.
- CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
- Antigen-targeted activation of Topo1 inhibitors via click chemistry
- Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry
- Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dos
Source: NIH RePORTER.
Company data compiled and maintained by Healthcare Discovery.
